ATHA:NSD-Athira Pharma, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 18.06

Change

+0.64 (+3.67)%

Market Cap

USD 0.62B

Volume

0.12M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and stop neurodegradation. Its lead product candidate is ATH-1017, a blood brain barrier-penetrating, small hepatocyte growth factor/MET activator that is in LIFT-AD Phase II/III and ACT-AD Phase II clinical trials for the treatment of mild-to-moderate Alzheimer's disease, as well as in clinical development for Parkinson's disease. The company also develops product candidates, which are in preclinical stage, including ATH-1019/ATH-1020 for neuropsychiatric conditions; and ATH-1018 for peripheral nervous system disorders, such as neuropathy. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-04-21 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+12.72 (+8.11%)

USD61.85B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

-0.40 (-0.18%)

USD56.98B 21.40 15.53
REGN Regeneron Pharmaceuticals, Inc

+2.06 (+0.41%)

USD54.04B 16.53 12.83
ALXN Alexion Pharmaceuticals, Inc

+1.90 (+1.14%)

USD36.79B 61.23 35.79
BNTX BioNTech SE

+5.62 (+3.60%)

USD36.10B -99,999.99 N/A
BGNE BeiGene, Ltd

+9.25 (+3.16%)

USD27.46B N/A N/A
SGEN Seagen Inc

+2.73 (+1.89%)

USD26.25B 42.96 35.78
RPRX Royalty Pharma plc

+1.34 (+3.23%)

USD25.16B 22.60 15.19
GMAB Genmab A/S

+0.82 (+2.29%)

USD23.17B 26.59 3.31
CVAC CureVac N.V

+2.16 (+1.95%)

USD21.12B N/A N/A

ETFs Containing ATHA

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -47.27% 4% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.27% 4% F 3% F
Trailing 12 Months  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) N/A N/A N/A N/A N/A
Risk Adjusted Return N/A N/A N/A N/A N/A
Market Capitalization 0.62B 63% D 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.25 80% B- 61% D-
Price / Cash Flow Ratio -25.63 85% B 87% B+
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -14.69% 87% B+ 39% F
Return on Invested Capital -14.58% 80% B- 31% F
Return on Assets -8.87% 86% B 29% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 2.86 56% F 40% F
Short Percent 2.91% 78% C+ 55% F
Beta N/A N/A N/A N/A N/A
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

What to not like:
Negative cashflow

The company had negative total cash flow in the most recent four quarters.